Surgical prevention strategies in ovarian cancer.
Abstract Given the current lack of effective screening for ovarian cancer, surgical removal of at-risk tissue is the most successful strategy to decrease risk of cancer development. However, the optimal timing of surgery and tissues to remove, as well as the appropriate patients to undergo preventive procedures are poorly understood. In this review, we first discuss the origin and precursors of ovarian epithelial carcinomas, focusing on high-grade serous carcinomas and endometriosis-associated carcinomas, which cause the majority of the mortality and incidence of ovarian cancer. In addition, we summarize the impli...
Source: Gynecologic Oncology - August 4, 2018 Category: Cancer & Oncology Authors: Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS Tags: Gynecol Oncol Source Type: research

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapaj ós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.
CONCLUSIONS: CVSC had high acceptability and high prevalence of hrHPV types in women living in the Tapajós region, Amazon, Brazil. PMID: 30087059 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 4, 2018 Category: Cancer & Oncology Authors: Rodrigues LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, Oliveira NS, Chavez-Juan E, Da Silva DM, Kast WM, Nicol AF, Pilotto JH Tags: Gynecol Oncol Source Type: research

Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
PMID: 30087060 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 4, 2018 Category: Cancer & Oncology Authors: Matsuoka A, Tate S, Nishikimi K, Shozu M Tags: Gynecol Oncol Source Type: research

Human papillomavirus infection mediates response and outcome of vulvar squamous cell carcinomas treated with radiation therapy.
This study evaluates if p16-positivity, a surrogate for HPV, predicts for better response rates to chemoradiation therapy and survival. MATERIALS AND METHODS: We conducted a retrospective chart review of women treated with neoadjuvant or definitive chemoradiation (CRT) therapy from 2000 to 2016 for VSCC. p16 stain-positivity was defined as diffuse strong "block" immunoreactivity within invasive tumor. RESULTS: Seventy-three women with median follow-up of 13.4 months were analyzed. Thirty-three (45.2%) had p16+ tumors. Median age was 73 years (range: 37-89); with p16+ tumors, the median age was 60 ...
Source: Gynecologic Oncology - August 3, 2018 Category: Cancer & Oncology Authors: Horne ZD, Dohopolski MJ, Pradhan D, Bhargava R, Edwards RP, Kelley JL, Comerci JT, Olawaiye AB, Courtney-Brooks MB, Bockmeier MM, Berger JL, Taylor SE, Sukumvanich P, Beriwal S Tags: Gynecol Oncol Source Type: research

Validation of PROMIS emotional distress short form scales for cervical cancer.
CONCLUSIONS: The PROMIS depression and anxiety short forms reliably and validly assess cervical cancer-specific emotional distress, capture salient features of distress in this population, and perform as well or better than legacy measures. PMID: 30078504 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 2, 2018 Category: Cancer & Oncology Authors: Wilford J, Osann K, Hsieh S, Monk B, Nelson E, Wenzel L Tags: Gynecol Oncol Source Type: research

Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
CONCLUSIONS: Systemic inflammation and TILs are early determinants of OS in HGSOC. Other variables such as the quality of debulking surgery and PDL1 also improve survival of patients. Regarding TIL sub-populations, intraepithelial CD4+ cells are associated to an increase in both PFS and OS. We also confirmed previous reports that demonstrate intraepithelial CD8+ cells correlate with an increase on PFS in ovarian cancer. A combined score using systemic inflammation and TILs may be of prognostic value for HGSOC patients. PMID: 30078505 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 2, 2018 Category: Cancer & Oncology Authors: Pinto MP, Balmaceda C, Bravo ML, Kato S, Villarroel A, Owen GI, Roa JC, Cuello MA, Ibañez C Tags: Gynecol Oncol Source Type: research

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
CONCLUSIONS: The PORTEC-4a trial design was proven feasible with a satisfactory patient acceptance rate and an optimized workflow of the determination of the molecular-integrated risk profile. PORTEC-4a is the first randomized trial to investigate use of a molecular-integrated risk profile to determine adjuvant treatment in EC. PMID: 30078506 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 2, 2018 Category: Cancer & Oncology Authors: Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL, PORTEC Study Group Tags: Gynecol Oncol Source Type: research

BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
CONCLUSIONS: We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management. PMID: 30078507 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 2, 2018 Category: Cancer & Oncology Authors: Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, Yang L, Jiao Z, Luo J, Zi Y, Sun G, Zhang J, Shi Y, Liu J Tags: Gynecol Oncol Source Type: research

Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
CONCLUSIONS: Many high-risk women do not receive GCR despite a high rate of germline mutations among these women. Improving GCR among high-risk women will lead to more subsequent GT to identify more Lynch syndrome families and prevent additional cancers. Among our ethnically diverse cohort, two women diagnosed with LS had retained MMR protein expression. GCR should be offered to women who possess high-risk characteristics despite normal MMR protein expression. PMID: 30077346 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - August 1, 2018 Category: Cancer & Oncology Authors: Lee J, Gubernick LR, Brodsky AL, Fehniger JE, Levine DA, Gerber D, Asgari SA, Cantor A, Martineau JT, Ginsburg OM, Smith JA, Pothuri B Tags: Gynecol Oncol Source Type: research

The limits of aggressive surgical cytoreduction.
PMID: 30025830 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 23, 2018 Category: Cancer & Oncology Authors: Levine DA Tags: Gynecol Oncol Source Type: research

Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy.
CONCLUSIONS: Off-line assessment of MI and CSI in women with endometrial cancer using 3D-VCI has lower interrater reliability and lower accuracy than 2D-TVU video clip assessment. Since accuracy was correlated to the number of cases assessed annually it is advised to centralize these examinations to high-volume centres. PMID: 30029961 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 17, 2018 Category: Cancer & Oncology Authors: Green RW, Valentin L, Alcazar JL, Chiappa V, Erdodi B, Franchi D, Frühauf F, Fruscio R, Guerriero S, Graupera B, Jakab A, di Legge A, Ludovisi M, Mascilini F, Pascual MA, van den Bosch T, Epstein E Tags: Gynecol Oncol Source Type: research

Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
CONCLUSIONS: These results provide a preclinical rationale for improved treatment modalities using olaparib as an effective radiosensitizer in HGSOC, particularly in tumors with BRCA1-deficiencies. PMID: 30025822 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 16, 2018 Category: Cancer & Oncology Authors: Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C Tags: Gynecol Oncol Source Type: research

The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
CONCLUSION: Our review demonstrates that IGBT is an effective strategy to improve locoregional control with limited long-term sequelae in patients with locally advanced extensive cervical cancer in the setting of a developing country. PMID: 30017538 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 14, 2018 Category: Cancer & Oncology Authors: Tiwari R, Narayanan GS, Jayakumar V, Narayanan S, Vishwanathan B, Mandal SK, Babu S, Ramya V, George D Tags: Gynecol Oncol Source Type: research

Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
CONCLUSIONS: In patients undergoing radical hysterectomy and pelvic lymphadenectomy for stage IA2-IB2 cervical cancer, para-aortic lymph node dissection is not warranted based on the low risk of isolated metastatic disease, and lack of survival benefit associated with the procedure. PMID: 30017539 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 14, 2018 Category: Cancer & Oncology Authors: Del Carmen MG, Pareja R, Melamed A, Rodriguez J, Greer A, Clark RM, Rice LW Tags: Gynecol Oncol Source Type: research

HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
CONCLUSIONS: Contrary to the present findings, former studies showed that mutations in MED12 and overexpression of HMGA2 are mutually exclusive. Here, we observed that overexpression of HMGA2 mRNA in tumors measured by quantitative PCR and compared to myometrium is a common phenomenon in fibroids and is frequently associated with MED12 mutations. In addition, the common clonal origin of tumors overexpressing HMGA2 mRNA and its expression in few myometrial tissue points to HMGA2 up-regulation as an early event in leiomyoma tumorigenesis. PMID: 30017537 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 12, 2018 Category: Cancer & Oncology Authors: Galindo LJ, Hernández-Beeftink T, Salas A, Jung Y, Reyes R, de Oca FM, Hernández M, Almeida TA Tags: Gynecol Oncol Source Type: research

Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
Abstract OBJECTIVE: To assess the association between patterns of distant metastases and overall survival in metastatic ovarian cancer and identify prognostic factors for site-specific distant metastases. METHODS: Data was obtained from the SEER database between 2010 and 2014. Univariate and multivariate Cox proportional hazard models were used to identify variables associated with overall survival. Survival times between different groups were compared using Kaplan-Meier analysis and log-rank tests. RESULTS: We analyzed 1481 patients. The most common distant metastatic site was liver, followed by distant...
Source: Gynecologic Oncology - July 9, 2018 Category: Cancer & Oncology Authors: Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, Lou G, Li Z, Hou Y, Li K Tags: Gynecol Oncol Source Type: research

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
CONCLUSIONS: Our study provides evidence that delayed initiation of adjuvant chemotherapy is an independent prognostic factor for worse overall survival after complete (interval)debulking surgery. We advise to start adjuvant chemotherapy within five to six weeks after debulking surgery. PMID: 30001834 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 9, 2018 Category: Cancer & Oncology Authors: Timmermans M, van der Aa MA, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF, Sonke GS Tags: Gynecol Oncol Source Type: research

Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
CONCLUSION: Overall, inter-rater agreement for tumor type and grade for archival tissue specimens was good. Agreement between the consensus review and original pathology reports was lower. Factors contributing to grading disagreement included non-serous histotype, absence of bizarre atypia, and absence of SET architecture. PMID: 30001835 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 9, 2018 Category: Cancer & Oncology Authors: Barnard ME, Pyden A, Rice MS, Linares M, Tworoger SS, Howitt BE, Meserve EE, Hecht JL Tags: Gynecol Oncol Source Type: research

The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis.
CONCLUSIONS: Car-RT showed a poorer tumor response and a trend toward inferior survival compared with Cis-RT in the treatment of cervical cancer. However, this evidence was limited by the imbalance among studies. Due to the encouraging efficacy and low toxicity, carboplatin is a suitable concurrent agent for patients with contraindications to cisplatin. PMID: 29996970 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 8, 2018 Category: Cancer & Oncology Authors: Xue R, Cai X, Xu H, Wu S, Huang H Tags: Gynecol Oncol Source Type: research

Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
CONCLUSIONS: Detecting pathogenic mutations in 13/50 genes examined at comparable frequencies in hrHPV(+) and hrHPV(-) tumors suggest that genetic mechanisms of the two routes of VSCC pathogenesis may be similar, despite being initiated from different premalignant lesions. Importantly, our data provide a rationale for new anti-VSCC therapies targeting the PI3K/AKT/mTOR pathway. PMID: 29980281 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - July 3, 2018 Category: Cancer & Oncology Authors: Zięba S, Kowalik A, Zalewski K, Rusetska N, Goryca K, Piaścik A, Misiek M, Bakuła-Zalewska E, Kopczyński J, Kowalski K, Radziszewski J, Bidziński M, Góźdź S, Kowalewska M Tags: Gynecol Oncol Source Type: research

Cabozantinib in ovarian clear cell cancers: UnMET expectations.
PMID: 29935857 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 27, 2018 Category: Cancer & Oncology Authors: Secord AA, Previs RA, Nixon AB Tags: Gynecol Oncol Source Type: research

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Abstract A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed. PMID: 29937315 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 21, 2018 Category: Cancer & Oncology Authors: Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA Tags: Gynecol Oncol Source Type: research

Hormonal strategies in gynecologic cancer: Bridging biology and therapy.
PMID: 29933928 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 20, 2018 Category: Cancer & Oncology Authors: Nieves-Neira W, Kim JJ, Matei D Tags: Gynecol Oncol Source Type: research

Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.
Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers. Gynecol Oncol. 2018 Jun 20;: Authors: Rauh LA, Saks EJ, Nakad-Rodriguez D, Showalter TN, Duska LR Abstract OBJECTIVE: To determine whether distance to a tertiary care facility affects outcomes for locally advanced cervical cancer and to evaluate the impact of receiving care at non-specialized centers in rural communities. METHODS: Retrospective, single institution study of patients with locally advanced cervical cancer managed with chemo-r...
Source: Gynecologic Oncology - June 20, 2018 Category: Cancer & Oncology Authors: Rauh LA, Saks EJ, Nakad-Rodriguez D, Showalter TN, Duska LR Tags: Gynecol Oncol Source Type: research

Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 Jun 19;: Authors: Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ Abstract OBJECTIVES: To examine the relationship between volume of residual disease and oncologic outcomes among patients with advanced-stage epithelial ovarian/fallopian tube/primary peritoneal carcinoma undergoing primary debulking surgery (PDS). For patients that did not undergo a...
Source: Gynecologic Oncology - June 19, 2018 Category: Cancer & Oncology Authors: Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ Tags: Gynecol Oncol Source Type: research

Innovation in fertility-sparing oncology surgery: Traversing frontiers.
PMID: 29933929 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 19, 2018 Category: Cancer & Oncology Authors: Del Carmen MG Tags: Gynecol Oncol Source Type: research

Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
Abstract OBJECTIVE: To assess the performance of a symptom index (SI) and multivariate biomarker panel in the identification of ovarian cancer in women presenting for surgery with an adnexal mass. STUDY DESIGN: Prospective study of patients seen at a tertiary medical center. Following consent, patients completed an SI and preoperative serum was collected for individual markers (CA 125) and a second-generation FDA-cleared biomarker test (MIA2G). Results for the SI and MIA2G were correlated with operative findings and surgical pathology. Logistic regression modeling was performed to assess the interaction of th...
Source: Gynecologic Oncology - June 18, 2018 Category: Cancer & Oncology Authors: Urban RR, Pappas TC, Bullock RG, Munroe DG, Bonato V, Agnew K, Goff BA Tags: Gynecol Oncol Source Type: research

Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
CONCLUSIONS: Policies and programs should be designed to measure short- and long-term outcomes in this patient population to avoid bias in assigning patients to NACT-ICS to maintain low 30-day readmission rates. PMID: 29929923 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 18, 2018 Category: Cancer & Oncology Authors: Clark RM, Rice LW, Del Carmen MG Tags: Gynecol Oncol Source Type: research

Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
Abstract OBJECTIVES: Previous studies have identified age, nutritional status, and hematocrit as risk factors for unplanned ICU admission in gynecologic oncology patients. We sought to identify additional perioperative factors that can be predictive of unplanned ICU admission and its impact on outcomes in women with ovarian cancer undergoing ovarian cancer cytoreductive procedures. METHODS: This was a case-control study of patients with unplanned ICU admission after primary surgery for ovarian cancer from January 2007 to December 2013. Controls were selected in a 2:1 ratio matching for primary surgeon and dat...
Source: Gynecologic Oncology - June 18, 2018 Category: Cancer & Oncology Authors: Ross MS, Burriss ME, Winger DG, Edwards RP, Courtney-Brooks M, Boisen MM Tags: Gynecol Oncol Source Type: research

Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.
We present clinical outcomes of patients treated with image-based high dose-rate (HDR) brachytherapy using a MCVC. METHODS AND MATERIALS: Sixty patients with vaginal cancer (27% primary vaginal and 73% recurrence from other primaries) were treated with combination external beam radiotherapy (EBRT) and image-based HDR brachytherapy utilizing a MCVC if residual disease thickness was 7 mm or less after EBRT. All pts received 3D image-based BT to a total equivalent dose of 70-80 Gy. RESULTS: The median high-risk clinical target volume was 24.4 cm3 (interquartile range [IQR], 14.1), with a median dose to 90% of ...
Source: Gynecologic Oncology - June 18, 2018 Category: Cancer & Oncology Authors: Gebhardt BJ, Vargo JA, Kim H, Houser CJ, Glaser SM, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Comerci JT, Courtney-Brooks M, Beriwal S Tags: Gynecol Oncol Source Type: research

Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Abstract OBJECTIVE: To investigate the relationship between molecular subtype, intraperitoneal (IP) disease dissemination patterns, resectability, and overall survival (OS) in advanced high-grade serous ovarian cancer (HGSOC). METHODS: Patients undergoing primary surgery for stage III-IV HGSOC at Mayo Clinic from 1994 to 2011 were categorized into three IP disease dissemination patterns: upper abdominal or miliary; lower abdominal; and pelvic. Residual disease was defined as 0 (RD0), 0.1-0.5, 0.6-1.0, or>1 cm. Molecular subtypes were derived from Agilent 4x44k tumor mRNA expression profiles and categoriz...
Source: Gynecologic Oncology - June 17, 2018 Category: Cancer & Oncology Authors: Torres D, Wang C, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Konecny GE, Goode EL, Cliby WA Tags: Gynecol Oncol Source Type: research

The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
CONCLUSION: The results derived from TCGA data and mitochondrial DEPs data are consistent with the Warburg and reverse Warburg effects that cancer cells mainly rely on glycolysis and oxidative phosphorylation to produce energy. Also, this integrated lncRNA-miRNA-mRNA and lncRNA-binding protein-mRNA signatures might have important merit for insights into molecular mechanisms and clinical implications in ovarian cancer. PMID: 29921511 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Li N, Zhan X, Zhan X Tags: Gynecol Oncol Source Type: research

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992. PMID: 29921512 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM Tags: Gynecol Oncol Source Type: research

Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer.
CONCLUSION: ICG is an excellent tracer for SLN mapping in endometrial cancer. Advanced FIGO stage correlated with failed bilateral detection (p = 0.01). Suspicious lymph nodes should be removed regardless of the mapping. Care should be taken to ensure that SLN specimen actually contains nodal tissue and not only swollen lymphatic channels, as this represents a significant cause of failed SLN mapping. PMID: 29909967 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 14, 2018 Category: Cancer & Oncology Authors: Body N, Grégoire J, Renaud MC, Sebastianelli A, Grondin K, Plante M Tags: Gynecol Oncol Source Type: research

Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
CONCLUSION: The pilot established feasibility, acceptability, and some potential benefits of a new web-based app intervention for gynecological oncology postoperative care. PMID: 29903391 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 11, 2018 Category: Cancer & Oncology Authors: Graetz I, Anderson JN, McKillop CN, Stepanski EJ, Paladino AJ, Tillmanns TD Tags: Gynecol Oncol Source Type: research

First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive.
CONCLUSION: Hysterectomy as a first-line treatment is effective without salvage chemotherapy in 82.4% of women with low-risk non-metastatic GTN and can be presented as an alternative to single-agent chemotherapy when childbearing considerations have been fulfilled. In young patients, this therapeutic option should not be considered because single-agent chemotherapies are curative in nearly 100% of patients while maintaining fertility. PMID: 29887485 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 8, 2018 Category: Cancer & Oncology Authors: Bolze PA, Mathe M, Hajri T, You B, Dabi Y, Schott AM, Patrier S, Massardier J, Golfier F Tags: Gynecol Oncol Source Type: research

Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
CONCLUSIONS: In this study focusing on women with EC in the HR groups, we did not find a difference in the 5-year DFS when comparing the SLN-A strategy with S-LND. The SLN strategy did not seem to compromise the prognosis of patients with a higher risk of recurrence. PMID: 29887483 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2018 Category: Cancer & Oncology Authors: Buda A, Gasparri ML, Puppo A, Mereu L, De Ponti E, Di Martino G, Novelli A, Tateo S, Muller M, Landoni F, Papadia A Tags: Gynecol Oncol Source Type: research

Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.
Discussion of classification, surgical options, and adjuvant therapy is presented. PMID: 29887484 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2018 Category: Cancer & Oncology Authors: Michael Straughn J, Boitano T, Smith HJ, Dilley SE, Liang MI, Novak L Tags: Gynecol Oncol Source Type: research

Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
CONCLUSIONS: Patients diagnosed with dysgerminoma have an excellent OS, across all ages, even in the context of metastatic disease. Data from three large CTOs supports the investigation of carboplatin-based regimens in the frontline treatment of all patients with advanced-stage dysgerminoma to minimize treatment-related toxicities. PMID: 29884437 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 5, 2018 Category: Cancer & Oncology Authors: Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S Tags: Gynecol Oncol Source Type: research

Characteristics of Lynch syndrome associated ovarian cancer.
CONCLUSION: Ovarian cancer in women with LS has a wide age-range of onset, is usually diagnosed at an early stage with predominantly endometrioid type histology and a good overall survival. The early stage at diagnosis could not be attributed to annual gynecological surveillance. PMID: 29880284 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 4, 2018 Category: Cancer & Oncology Authors: Woolderink JM, De Bock GH, de Hullu JA, Hollema H, Zweemer RP, Slangen BFM, Gaarenstroom KN, van Beurden M, van Doorn HC, Sijmons RH, Vasen HFA, Mourits MJE Tags: Gynecol Oncol Source Type: research

Persistent chemotherapy-induced peripheral neuropathy: Are dose reductions and drug modifications our only options?
PMID: 29861308 [PubMed - in process] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 1, 2018 Category: Cancer & Oncology Authors: Donovan HS, Campbell GB Tags: Gynecol Oncol Source Type: research

Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.
We examined whether the Silva system is applicable to all endocervical adenocarcinomas, especially those not associated with HPV. METHODS: Complete slide sets from 341 surgical specimens of ECA were collected from 7 institutions worldwide. All specimens were associated with clinical records covering at least 5 years of follow-up. Tumors were classified as HPV-associated (HPVA) or not (NHPVA) by both morphology and detection of HPV using in situ hybridization. Recurrence and survival were analyzed by multivariate Mantel-Haenszel methods. RESULTS: Most specimens (292; 85.6%) were HPVA, while 49 (14.3%) were NHPVA...
Source: Gynecologic Oncology - May 30, 2018 Category: Cancer & Oncology Authors: Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Abu-Rustum NR, Pike MC, Soslow RA Tags: Gynecol Oncol Source Type: research

Endometrial cancer: Molecular markers and management of advanced stage disease.
Abstract Endometrial cancer is the most prevalent gynecologic cancer in the United States. Over the last 10 years, death rates from endometrial cancer have been rising about 1.4% per year. Traditionally endometrial cancer treatment has been driven by stage and histology. Recent studies have, however, shown that cancers of the same stage and histology have very distinct molecular and genomic profiles. Translational research is progressing rapidly and endometrial cancer-specific precision medicine is evolving. The first tissue agnostic therapy based on the molecular profile of the tumor was approved by the FDA thi...
Source: Gynecologic Oncology - May 27, 2018 Category: Cancer & Oncology Authors: Arend RC, Jones BA, Martinez A, Goodfellow P Tags: Gynecol Oncol Source Type: research

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
CONCLUSION: Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects. PMID: 29793803 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 21, 2018 Category: Cancer & Oncology Authors: Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA, Hereditary Ovarian Cancer Clinical Study Group Tags: Gynecol Oncol Source Type: research

Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
CONCLUSIONS: Our findings suggest that the assessment of mutations affecting TP53, KRAS, PIK3CA, ARID1A and POLE, and DNA MMR protein expression may be used to further aid the diagnosis and treatment decision-making of primary MOC. PMID: 29793804 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 21, 2018 Category: Cancer & Oncology Authors: Mueller JJ, Schlappe BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, Aghajanian C, DeLair D, Hussein YR, Soslow RA, Levine DA, Weigelt B Tags: Gynecol Oncol Source Type: research

An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology.
CONCLUSIONS: Immunohistochemistry is useful as an objective means for improved diagnostic reproducibility, accuracy, and precise classification in cases where the diagnosis with histochemical stains is inconclusive, providing a more reliable estimate of clinical outcomes. The diagnosis, in some cases, can be further refined by the use of molecular techniques leading to personalised medical treatments. PMID: 29792263 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 21, 2018 Category: Cancer & Oncology Authors: Kalampokas E, Payne F, Gurumurthy M Tags: Gynecol Oncol Source Type: research

Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors?
CONCLUSIONS: As in other endocrine tumors, ERβ may play a role in the pathogenesis of AGCT; it is crucial to understand estrogen receptor-mediated pathways before planning hormonal treatment strategies in AGCT. PMID: 29786517 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 18, 2018 Category: Cancer & Oncology Authors: Ciucci A, Ferrandina G, Mascilini F, Filippetti F, Scambia G, Zannoni GF, Gallo D Tags: Gynecol Oncol Source Type: research

Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
CONCLUSIONS: In patients nearing the end of life, there are significant associations between disease and treatment related symptoms and unmet patient needs, which do not change substantially over time. Careful exploration of specific end-of-life care needs can improve patient-centered care and QOL. PMID: 29778506 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 17, 2018 Category: Cancer & Oncology Authors: von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L Tags: Gynecol Oncol Source Type: research

Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments.
Abstract OBJECTIVE: To investigate the association of obesity and other comorbidities as well as route of surgery with postoperative outcomes, as well as 30- and 90-day inpatient cost of care after hysterectomy for endometrial cancer. METHODS: From the 2013 National Readmission Database release, patients who underwent hysterectomy for endometrial cancer were included. Obesity was classified as non-obese (body mass index [BMI] 
Source: Gynecologic Oncology - May 16, 2018 Category: Cancer & Oncology Authors: Rolston A, Spencer RJ, Kevin Reynolds R, Rice LW, Uppal S Tags: Gynecol Oncol Source Type: research

Financial toxicity - An overlooked side effect.
PMID: 29778508 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 16, 2018 Category: Cancer & Oncology Authors: Liang MI, Huh WK Tags: Gynecol Oncol Source Type: research